Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer

Experimental population:Advanced first-line HR+, HER2 metastatic breast cancer patients Research endpoint: Main research endpoint: PFS evaluated by researchers (according to RECIST 1.1 standard) Secondary study endpoint: ORR、CBR、DCR、OS The incidence of adverse events (AE) and severe adverse events (SAE) Exploratory study endpoint: Tumor infiltrating lymphocytes (sTIL) Peripheral blood lymphocyte ratio Distribution of fecal microbiota Research overall design:This study adopts a prospective, single arm design, and plans to include 36 postmenopausal or premenopausal/perimenopausal patients

Trial Details

NCT ID
NCT06495515
Phase
PHASE2
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Dalpiciclib,Toremifen
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Postmenopausal or premenopausal/perimenopausal female patients aged ≥ 18 years and ≤ 75 years old,
  • Meet one of the following conditions:
  • a) Previously underwent bilateral oophorectomy, or aged ≥ 60 years old; or b) Age\<60, natural postmenopausal state (defined as spontaneous …
  • c) Premenopausal or perimenopausal female patients can also be selected, but they must be willing to receive LHRH agonist treatment during the stud…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →